Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients With Unresectable Pancreatic Ductal Adenocarcinoma
Oncologist - United States
doi 10.1634/theoncologist.2018-0900
Full Text
Open PDFAbstract
Available in full text
Date
January 24, 2019
Authors
Publisher
Alphamed Press